Description
Linoleoyl glycine is an endogenous homolog of linoleoyl ethanolamide, an arachidonyl glycine. Arachidonyl glycine, the conjugate of arachidonic acid and glycine produced in mammalian skin, spinal cord and brain, is a structural counterpart of anandamide (AEA) that is reported to have analgesic activities in whole animal experiments. It has poor affinity for the central cannabinoid (CB1) receptor, high-affinity for the G protein-coupled receptor GPR-18, and is metabolically regulated by fatty acid amide hydrolase (FAAH) activity. Linoleoyl glycine inhibits the hydrolysis of AEA in FAAH-containing N18TG2 cell membranes (IC:50:~ 25 µM), which is less potent than that of arachidonyl glycine (IC:50:= 7 µM). The biological significance of linoleoyl glycine has not yet been determined